Deal-Making

Ins & outs: Emergent exec shake up following Bayview 483

Emergent announced multiple changes in leadership during its Q1 2021 earnings call to shareholders. Meanwhile, there are changes at Myeloid Therapeutics and Catamaran Bio. Sit back, relax, and enjoy BioProcess Insider’s Ins & Outs. Emergent BioSolutions had been contracted to make millions of doses of Johnson & Johnson and AstraZeneca’s respective vaccines from its Bayview, Maryland plant. However, production was halted at the facility in April after a US Food and Drug Administration (FDA) inspection resulted in a Form 483…

SBI hoping to kickstart digital bioprocessing revolution through aquila buy

Scientific Bioprocessing (SBI) says it is aiming to create a digital platform to enhance biopharmaceutical workflow through the acquisition of smart sensor and data analytics firm aquila biolabs. Life sciences tool supplier Scientific Industries, through its subsidiary SBI, has acquired aquila biolabs, adding smart sensors and data analytics software for bioprocessing along with facilities in Baesweiler, Germany. “From the earliest interactions with the aquila biolabs team, it became really apparent that we shared the vision of developing technologies that can…

Selecta conducts manufacturing review as it takes over MMA program

Selecta Biosciences will review a manufacturing issue stemming from a third party after taking over the rights to an methylmalonic acidemia (MMA) gene therapy program. Selecta Biosciences and Asklepios BioPharmaceutical (AskBio – acquired by Bayer in October 2020) entered a joint partnership in August 2019 to advance, produce and commercialize adeno-associated virus (AAV) gene therapies using technology platforms from both firms. While both companies’ will continue their collaboration to assess various gene therapy candidates, after a review of its portfolio…

Lack of AAV capacity drives $120m investment for Forge Biologics

Forge Biologics has closed $120 million in Series B financing to expand its AAV manufacturing capabilities and develop gene therapies. The gene therapy contract development manufacturing organization (CDMO) Forge Biologics has raised $120 million with finances led by RA Capital Management, Octagon Capital, Surveyor Capital (a Citadel company), and Marshall Wace. According to Forge, the funding will fast-track the expansion of its adeno-associated virus (AAV) manufacturing CDMO capabilities and capacity and work with its subsidiaries that are developing AAV gene…

Samsung Biologics and TG Therapeutics expand mAb manufacturing contract

Samsung Biologics and TG therapeutics have expanded their existing contract to manufacture Ublituximab, a monoclonal antibody drug to treat multiple sclerosis.  Korean Contract development manufacturing organization (CDMO) Samsung Biologics and US-based firm TG Therapeutics have expanded their 2018 contract to produce TG’s ublituximab (TG-1101), a monoclonal antibody (mAb) that targets an epitope on CD20-expressing B-cells. Samsung Biologics did not divulge ublituximab’s manufacturing process due to client confidentiality. However, a spokeswoman for the firm told BioProcess Insider it will “offer large-scale…

Avectas to develop cell engineering technology for CGT space

Avectas has received funding to develop a cell engineering technology platform to manufacture ‘off-the-shelf’ cell therapies for cancer treatment. Irish cell engineering firm Avectas is leading a project in partnership with the National Institute for Bioprocessing Research and Training (NIBRT) and Bluebridge Technologies, which will invest $8.7 million – including $5.3 million awarded by the Irish Government’s Disruptive Technology Innovation Fund (DTIF) – to develop the cell engineering platform Solupore. “Solupore is a comprehensive end-to-end cell engineering platform that comprises…

Sanofi to fill-finish up to 200m doses of Moderna’s COVID vaccine

Sanofi will supply fill-finish services for up to 200 million doses of Moderna’s COVID-19 vaccine mRNA-1273. French pharma giant Sanofi will use its site in Ridgefield, New Jersey to support manufacturing of Moderna’s cell-free COVID-19 vaccine, 1273, approved under Food and Drug Administration (FDA) emergency authorization. According to the firm, it could help manufacture up to 200 million doses of the COVID-19 vaccine starting from September 2021 through to April 2022. “While our utmost priority remains to advance our two COVID-19 vaccine…

Ins & outs: High level leadership changes at Novavax

Novavax has switched up its leadership with multiple changes. Meanwhile there are changes at Kyverna and Precision BioSciences. Put your feet up and enjoy BioProcess Insider’s Ins & Outs. US-based biotechnology company Novavax develops and commercializes various vaccines to treat infectious diseases such as Ebola, seasonal influenza, and COVID-19. The firm has its own COVID-19 vaccine candidate, NVX-CoV2373, which has not yet received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and is currently in two Phase III…

CDMO round-up: News from Lonza, MedPacto and Revolo Biotherapeutics

Lonza collaborates with Immunitas to develop candidate; MedPacto signs agreement with Samsung Biologics; Revolo Biotherapeutics chooses CordenPharma to manufacture its peptide and immune system resetting drug candidate. Great to have you here for Bioprocess Insider’s CDMO round-up. First up in our contract development manufacturing organization (CDMO) round-up is Lonza, which recently entered an agreement with Immunitas Therapeutics to support manufacturing of Immunitas’ lead program, IMT-009. IMT-099 is a monoclonal antibody that suppresses NK cells and T cells in the tumor microenvironment and…

Thermo Fisher to buy PPD to build in ‘high growth’ clinical services sector

Thermo says buying PPD will position it as leader in the “high growth” CRO sector and help it win more business from new and existing customers. Thermo Fisher Scientific announced its intention to buy contract research organization (CRO) PPD for $17.4 billion in a statement on Thursday, citing demand from pharma and biotechnology sector customers. Thermo Fisher’s CEO Marc Casper said “The acquisition of PPD is a natural extension for Thermo Fisher and will enable us to provide these customers…